{"slideshow_credits": null, "snippet": "The strategic rationale of the merger makes sense, but the estimated $30 billion of value creation from cost savings is too generous.", "abstract": null, "section_name": "Business Day", "print_page": null, "document_type": "article", "byline": {"person": [{"firstname": "Kevin", "role": "reported", "lastname": "ALLISON", "rank": 1, "organization": ""}], "original": "By KEVIN ALLISON"}, "web_url": "http://www.nytimes.com/2015/12/12/business/dealbook/dow-and-dupont-test-the-limits-of-deal-making.html", "lead_paragraph": "The strategic rationale of the merger makes sense, but the estimated $30 billion of value creation from cost savings is too generous.", "headline": {"main": "Dow and DuPont Test the Limits of Deal-Making", "content_kicker": "Breakingviews", "kicker": "Breakingviews"}, "_id": "566afae438f0d857ec8b0c0a", "word_count": "401", "multimedia": [], "pub_date": "2015-12-12T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "rank": "1"}, {"name": "organizations", "value": "Dow Chemical Company", "is_major": "N", "rank": "2"}, {"name": "organizations", "value": "DuPont Co", "is_major": "N", "rank": "3"}], "blog": [], "subsection_name": "DealBook", "type_of_material": "News"}